About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
H
Oral Abstract RES 166: Differencies in IGHV Gene Usage and Stereoptypic Receptors in CLL and SMZL
By
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
FEATURING
Hunan Julhakyan
By
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
FEATURING
Hunan Julhakyan
18 views
November 5, 2018
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
08:18
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…
Feat.
A. Zhou
09:27
ASH 2022 Conference Coverage
MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…
Feat.
M. McMullin
16:25
Northwestern Medicine Oncology and Hematology
Diagnosis and Goals of Therapy in PV
Feat.
B. Stein
26:58
Total Health
Update on Cellular Therapy in Lymphoma
Feat.
B. Randolph
36:40
Penn Medicine Abramson Cancer Center
Penn Medicine Abramson Cancer Center Updates on Managing CLL/SLL Wit…
Feat.
J. Carter,
M. Hughes
10:49
Monia Marchetti
Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
44:20
Yale Cancer Center
CLL: Genotype to Phenotype and Beyond
Feat.
C. Wu
03:42
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "BELLWAVE-003 - A Phase 2 Dose Escalation,…
Feat.
G. Perini
11:12
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Next Questions: Indolent B-Cell Lymphoma
Feat.
L. Nastoupil
14:36
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
The Latest Data on New Therapies in FL and MZL
Feat.
J. Carter
16:11
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Treatment Options for Marginal Zone Lymphoma
Feat.
E. Zucca
11:42
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Impact of Large Cells and Ki-67% on Outcome…
Feat.
N. Epperla
22:53
SOHO Turkey 2023
SOHO Turkey 2023: Marginal Zone Lymphoma & Mantle Cell Lymphoma
Feat.
O. Hermine
17:41
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Manage Follicular, Marginal Zone and Mantle C…
Feat.
S. Luminari
21:46
SOHO 2022 Tenth Annual Meeting
SOHO 2022: CAR T-Cells in Indolent B-Cell Lymphomas
Feat.
J. Abramson
08:51
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Long-Term Outcomes After Haplo-SCT for Hematologic Malign…
Feat.
S. Saengboon
08:34
ASH 2022 Conference Coverage
ASH 2022: Zanubrutinib in Acalabrutinib-Intolerant Patients With B-C…
Feat.
M. Shadman
11:33
Alison Duffy
Adherence and Toxicity Assessment in CLL: Tips From an Oncology Clin…
19:21
SOHO Brazil 2023
2023 SOHO® Brazil: "CAR-T Therapy in MCL, FL, and MZL"
Feat.
B. Shah
